View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Theme
  2. Macro
  3. Covid-19
June 2, 2020

Coronavirus company new summary – Gilead reports Phase III results for remdesivir – Emergent wins US Government contract for vaccine manufacturing

By Allie Nawrat

Gilead Sciences has reported positive top-line data from the Phase III SIMPLE clinical trial of remdesivir in hospitalised patients with moderate Covid-19 pneumonia. According to the results, patients on the five-day remdesivir course were 65% more likely to have clinical improvement at day 11 than those on the standard of care treatment.

The US Government has awarded a $628m contract to Emergent BioSolutions for domestic production of Covid-19 vaccine candidates through 2021. As part of the contract, Emergent will provide molecule-to-market CDMO services and commit manufacturing capacity, valued at about $542.7m.

The Russian Direct Investment Fund (RDIF) and the ChemRar Group have committed to deliver 60,000 courses of Avifavir this month to hospitals across the country. Avifavir, a generic version of Avigan (Favipiravir), recently secured the Ministry of Health of the Russian Federation registration certificate.

Tonix Pharmaceuticals has entered an agreement with Fujifilm Diosynth Biotechnologies to manufacture its Covid-19 vaccine candidate, TNX-1800, for clinical trials. Fujifilm will manufacture and stock the vaccine candidate at its College Station, Texas, site.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology